Real-world effectiveness of maternal genetically inactivated acellular pertussis vaccination in protecting infants under three months of age: a case-control study using concurrent community-based and test-negative controls
- 1Su-ngai Kolok Hospital, Narathiwat Provincial Public Health Office, Su- ngai Kolok, Narathiwat Thailand
- 2Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla Thailand
Abstract
Purpose: Infants too young for primary vaccination face the highest risk of severe pertussis and death. While maternal vaccination is the primary protective strategy, the real-world vaccine effectiveness (VE) of acellular pertussis (aP) vaccines in Thailand (including recombinant aP (aPgen)) remains unknown. We aimed to evaluate the VE of the aP vaccine in protecting infants under 3 months of age against symptomatic pertussis.
Methods: This case-control study was conducted in the Narathiwat Province, Thailand, during a pertussis outbreak between September 2023 and October 2024. Participants included 33 symptomatic, polymerase chain reaction (PCR)-confirmed cases, 330 asymptomatic, community-matched controls (for primary comparison), and 41 symptomatic, test-negative controls (for sensitivity simulation). Maternal vaccination with aP vaccine during pregnancy was evaluated against no pertussis vaccination. The main outcome measures were symptomatic PCR-confirmed pertussis. VEs were estimated using a logistic regression model with inverse probability of treatment weighting.
Results: All vaccinated mothers (98 of 404) received aPgen (94% for standalone aPgen). The VE of the maternal aPgen vaccination against symptomatic-PCR confirmed pertussis was 95.3% (95% CI: 64.7%, 99.4%; p = 0.003). A post-hoc E-value sensitivity analysis indicated that it was unlikely that any residual or unmeasured confounders could explain away the statistically significant VE suggesting a robustness of the observed VE.
Conclusion: Maternal aPgen vaccination during pregnancy was highly likely to provide robust VE against symptomatic-PCR confirmed pertussis in infants during the first three months of life. These findings support the maternal pertussis vaccination with recombinant aP vaccines as effective strategy in Thailand and could be considered for other regions.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s15010-026-02868-x.
Related
- Real-world effectiveness of Paxlovid in protecting Long COVID for outpatient adult patients: A target trial emulation study from the RECOVER Initiative
- Cost-effectiveness and budget impact analyses of strategies to improve measles vaccination coverage in Kenya
- Effectiveness of the PPR Sungri-96 Vaccine in Sheep and Goats in India: A Nationwide Post-Vaccination Seromonitoring Study Towards PPR Elimination.
- Effectiveness of community-based delivery of mass dog vaccination to prevent rabies: A cluster randomized controlled trial
- Heat-Inactivated Lactiplantibacillus plantarum (RSB11) as a Multifunctional Postbiotic: Anti-Inflammatory Effects Compared with Live RSB11 Across Multiple Human Cell Models
BibTeX
@article{phiriyasart2026realworld,
title = {{Real-world effectiveness of maternal genetically inactivated acellular pertussis vaccination in protecting infants under three months of age: a case-control study using concurrent community-based and test-negative controls}},
author = {Farooq Phiriyasart and Virasakdi Chongsuvivatwong and Ponlagrit Kumwichar},
journal = {Infection},
year = {2026},
month = jul,
doi = {10.1007/s15010-026-02868-x},
url = {https://doi.org/10.1007/s15010-026-02868-x},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-world effectiveness of maternal genetically inactivated acellular pertussis vaccination in protecting infants under three months of age: a case-control study using concurrent community-based and test-negative controls
AU - Farooq Phiriyasart
AU - Virasakdi Chongsuvivatwong
AU - Ponlagrit Kumwichar
PY - 2026
DA - 2026/07/27
JO - Infection
DO - 10.1007/s15010-026-02868-x
UR - https://doi.org/10.1007/s15010-026-02868-x
AB - Purpose: Infants too young for primary vaccination face the highest risk of severe pertussis and death. While maternal vaccination is the primary protective strategy, the real-world vaccine effectiveness (VE) of acellular pertussis (aP) vaccines in Thailand (including recombinant aP (aPgen)) remains unknown. We aimed to evaluate the VE of the aP vaccine in protecting infants under 3 months of age against symptomatic pertussis. Methods: This case-control study was conducted in the Narathiwat Province, Thailand, during a pertussis outbreak between September 2023 and October 2024. Participants included 33 symptomatic, polymerase chain reaction (PCR)-confirmed cases, 330 asymptomatic, community-matched controls (for primary comparison), and 41 symptomatic, test-negative controls (for sensitivity simulation). Maternal vaccination with aP vaccine during pregnancy was evaluated against no pertussis vaccination. The main outcome measures were symptomatic PCR-confirmed pertussis. VEs were estimated using a logistic regression model with inverse probability of treatment weighting. Results: All vaccinated mothers (98 of 404) received aPgen (94% for standalone aPgen). The VE of the maternal aPgen vaccination against symptomatic-PCR confirmed pertussis was 95.3% (95% CI: 64.7%, 99.4%; p = 0.003). A post-hoc E-value sensitivity analysis indicated that it was unlikely that any residual or unmeasured confounders could explain away the statistically significant VE suggesting a robustness of the observed VE. Conclusion: Maternal aPgen vaccination during pregnancy was highly likely to provide robust VE against symptomatic-PCR confirmed pertussis in infants during the first three months of life. These findings support the maternal pertussis vaccination with recombinant aP vaccines as effective strategy in Thailand and could be considered for other regions. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s15010-026-02868-x.
SN - 0300-8126
SN - 1439-0973
ER -